Virtu Financial BD LLC recently announced the acquisition of new stake in Altamira Therapeutics Ltd. (NASDAQ:CYTO). The institutional investor has increased its shareholding in the Healthcare company by 867.29% to 6239.0 shares with purchase of 5594.0 shares. This fresh investment now brings its stake to 0.58% valued currently at $30259.0. In addition, Citadel Securities LLC raised its holdings by 3241.0 to 3241.0 shares. And Morgan Stanley & Co. LLC has lifted its position by 487.23% or 2022.0 shares – to 2437.0 shares.
With over 0.44 million Altamira Therapeutics Ltd. (CYTO) shares trading Tuesday and a closing price of $3.53 on the day, the dollar volume was approximately $1.55 million. The shares have shown a negative half year performance of -57.98% and its price on 01/24/23 lost nearly -29.12%. Currently, there are 1.17M common shares owned by the public and among those 1.09M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for CYTO have a consensus price objective of $286.10. The analysts have set the share’s price value over the next 12 months at a high of $286.10 and a low of $286.10. But an upside of 98.77% will see the stock hit the forecast high price target while median target price for the stock is $286.10.
Fidelity Nasdaq Composite Index F owns 943.0 shares of the company’s stock, all valued at over $4574.0.
Shares of Altamira Therapeutics Ltd. (NASDAQ: CYTO) opened at $2.95, down -$2.03 from a prior closing price of $4.98. However, the script later moved the day high at 3.8000, down -29.12%. The company’s stock has a 5-day price change of -30.24% and -66.04% over the past three months. CYTO shares are trading -27.22% year to date (YTD), with the 12-month market performance down to -86.83% lower. It has a 12-month low price of $3.95 and touched a high of $43.00 over the same period. CYTO has an average intraday trading volume of 58.58K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -30.59%, -32.93%, and -62.98% respectively.
Institutional ownership of Altamira Therapeutics Ltd. (NASDAQ: CYTO) shares accounts for 1.90% of the company’s 1.17M shares outstanding. Mutual fund holders own 0.09%, while other institutional holders and individual stakeholders account for 1.86% and — respectively.
It has a market capitalization of $3.95M and a beta (3y monthly) value of 1.60. The earnings-per-share (ttm) stands at -$26.83. Price movements for the stock have been influenced by the stock’s volatility, which stands at 13.47% over the week and 10.23% over the month.
Analysts forecast that Altamira Therapeutics Ltd. (CYTO) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and $0 for 2022. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0.